- Adjusted EBIT of EU825 million, up 8.8% year-over-year, but below the estimate of EU865.8 million.
- Imaging adjusted EBIT of EU594 million, down 5.4% year-over-year, below the estimate of EU651.9 million.
- Diagnostics adjusted EBIT of EU82 million, significantly up from EU6 million year-over-year, exceeding the estimate of EU54.4 million.
- Advanced Therapies adjusted EBIT of EU66 million, down 11% year-over-year, below the estimate of EU83.1 million.
- Revenue of EU5.42 billion, up 4.3% year-over-year, but below the estimate of EU5.53 billion.
- Imaging sales of EU2.98 billion, up 4% year-over-year, below the estimate of EU3.03 billion.
- Advanced Therapies sales of EU480 million, down 0.6% year-over-year, below the estimate of EU509.9 million.
- Diagnostics sales of EU1.11 billion, up 1.5% year-over-year, slightly below the estimate of EU1.12 billion.
- Comparable sales increased by 4.3%, below the estimate of 6.97% growth.
- Earnings per share (EPS) of EU0.42, matching the estimate, and slightly up from EU0.40 year-over-year.
- Adjusted EBIT margin at 15.2%, up from 14.6% year-over-year.
- Adjusted EPS of EU0.52, in line with the estimate but down from EU0.55 year-over-year.
- Free cash flow surged to EU546 million, up 92% year-over-year.
- Varian sales at EU927 million, up 10% year-over-year, slightly below the estimate of EU937.9 million.
- Varian adjusted EBIT of EU154 million, up 51% year-over-year, above the estimate of EU149.3 million.
- Year forecast still expects comparable sales growth between 4.5% and 6.5%, and adjusted EPS between EU2.10 and EU2.30.
- For Imaging, revenue growth now expected between 4.5% and 5.5%, down from the previous forecast of 6% to 8% growth.
- Tax rate forecast adjusted to between 22% and 24%, down from the previous forecast of 24% to 26%.
- CEO Bernd Montag highlighted strong performance from Varian and Diagnostics despite order delays in China, confirming the company’s financial outlook.
A look at Siemens Healthineers Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Siemens Healthineers, a leading medical technology company, is poised for a positive long-term outlook based on its Smartkarma Smart Scores. With a strong emphasis on growth and dividend payouts, the company scores high in these areas, indicating potential for sustained development and investor returns. Additionally, its momentum and resilience scores suggest a stable operational performance and consistent market presence, further adding to its appeal.
Siemens Healthineers’ diverse portfolio of offerings, including medical imaging and digital health solutions, positions it well in the healthcare industry. The company’s global reach and focus on innovative technologies place it in a favorable position for continued growth and value creation. Investors looking for a stable yet growing player in the medical technology sector may find Siemens Healthineers to be an attractive long-term investment option.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
